Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Chemotherapy is an essential postoperative treatment for pancreatic cancer, while due to the lack of effective drug evaluation platforms, the therapeutic outcomes are hampered by tumor heterogeneity among individuals. Here, a novel microfluidic encapsulated and integrated primary pancreatic cancer cells platform is proposed for biomimetic tumor 3D cultivation and clinical drug evaluation. These primary cells are encapsulated into hydrogel microcapsules of carboxymethyl cellulose cores and alginate shells based on a microfluidic electrospray technique. Benefiting from the good monodispersity, stability, and precise dimensional controllability of the technology, the encapsulated cells can proliferate rapidly and spontaneously form 3D tumor spheroids with highly uniform size and good cell viability. By integrating these encapsulated tumor spheroids into a microfluidic chip with concentration gradient channels and culture chambers, dynamic and high‐throughput drug evaluation of different chemotherapy regimens could be realized. It is demonstrated that different patient‐derived tumor spheroids show different drug sensitivity on‐chip, which is significantly consistent with the clinical follow‐up study after the operation. The results demonstrate that the microfluidic encapsulated and integrated tumor spheroids platform has great application potential in clinical drug evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943
Vatine, G. D., Barrile, R., Workman, M. J., Sances, S., Barriga, B. K., Rahnama, M., Barthakur, S., Kasendra, M., Lucchesi, C., Kerns, J., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.05.011 · Cited by 632
Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids
Schuster, B., Junkin, M., Kashaf, S. S., Romero-Calvo, I., Kirby, K., Matthews, J., Weber, C. R., Rzhetsky, A., White, K. P., & Tay, S. (2020) · Nature Communications · doi:10.1038/s41467-020-19058-4 · Cited by 424
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369
Vascularized cancer on a chip: the effect of perfusion on growth and drug delivery of tumor spheroid
Nashimoto, Y., Okada, R., Hanada, S., Arima, Y., Nishiyama, K., Miura, T., & Yokokawa, R. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119547 · Cited by 332
Charoen, K. M., Fallica, B., Colson, Y. L., Zaman, M. H., & Grinstaff, M. W. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.038 · Cited by 187
Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery
Agarwal, P., Wang, H., Sun, M., Xu, J., Zhao, S., Liu, Z., Gooch, K. J., Zhao, Y., Lu, X., & He, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00824 · Cited by 168
Self-citationCancer-on-a-chip systems at the frontier of nanomedicine
Zhang, Y. S., Zhang, Y.-N., & Zhang, W. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.011 · Cited by 127
Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies
Prince, E., Kheiri, S., Wang, Y., Xu, F., Cruickshank, J., Topolskaia, V., Tao, H., Young, E. W. K., McGuigan, A. P., Cescon, D. W., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202101085 · Cited by 121
Wang, Y., Wu, D., Wu, G., Wu, J., Lu, S., Lo, J., He, Y., Zhao, C., Zhao, X., Zhang, H., et al. (2020) · Theranostics · doi:10.7150/thno.38736 · Cited by 93
Self-citationHuman‐on‐Leaf‐Chip: A Biomimetic Vascular System Integrated with Chamber‐Specific Organs
Mao, M., Bei, H. P., Lam, C. H., Chen, P., Wang, S., Chen, Y., He, J., & Zhao, X. (2020) · Small · doi:10.1002/smll.202000546 · Cited by 71
Cited by
Microfluidic systems for modeling digestive cancer: a review of recent progress
Razavi, Z., Soltani, M., Pazoki-Toroudi, H., & Dabagh, M. (2024) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ad6f15 · Cited by 24
Shi, Q., Xia, Y., Wu, M., Pan, Y., Wu, S., Lin, J., Kong, Y., Yu, Z., Zan, X., Liu, P., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.100958 · Cited by 14
“The porous nature of hydrogel enables cell entrapment, facilitates nutrient exchange, and promotes metabolic excretion [24].”
BackgroundBiomacromolecular hydrogel scaffolds from microfluidics for cancer therapy: A review
Hao, S., Shi, L., Li, J., Shi, J., Kuang, G., Liang, G., & Gao, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136738 · Cited by 7
Metadata
- Authors
- Song, T., Zhang, H., Luo, Z., Shang, L., & Zhao, Y.
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2023-02-19
- Volume
- 10
- Issue
- 12
- Pages
- e2206004-e2206004
- ISSN
- 2198-3844 (ISSN-L)
- OpenAlex
- W4321350257
- Cited by
- 63
- References
- 13
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.